(XBI) S&P Biotech - Overview
Etf: Biotech Stocks, Healthcare Sector, Pharmaceutical
Dividends
| Dividend Yield | 0.36% |
| Yield on Cost 5y | 0.13% |
| Yield CAGR 5y | 82.73% |
| Payout Consistency | 49.1% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 26.5% |
| Relative Tail Risk | 2.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.16 |
| Alpha | 22.04 |
| Character TTM | |
|---|---|
| Beta | 0.863 |
| Beta Downside | 0.732 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.99% |
| CAGR/Max DD | 0.39 |
Description: XBI S&P Biotech January 09, 2026
The SPDR S&P Biotech ETF (XBI) seeks to replicate the S&P Biotechnology Select Industry Index by using a sampling methodology that invests at least 80 % of its assets in the index’s constituents, effectively providing broad exposure to the U.S. biotech segment of the S&P Total Market Index.
Key quantitative traits of XBI include an equal-weighting scheme that caps any single holding at roughly 1 % of assets, an expense ratio of 0.35 %, and a portfolio of about 140 biotech companies spanning early-stage innovators to mature firms. Recent performance has been driven by a surge in FDA approvals and robust venture capital inflows, while sector valuation is sensitive to interest-rate expectations and the pace of R&D spending, which averaged $140 billion in 2023 across U.S. biotech firms.
For a deeper dive into XBI’s risk-adjusted returns and how its exposure aligns with current biotech macro trends, you might explore the analytics on ValueRay.
What is the price of XBI shares?
Over the past week, the price has changed by -0.40%, over one month by +4.80%, over three months by +16.30% and over the past year by +39.82%.
Is XBI a buy, sell or hold?
What are the forecasts/targets for the XBI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 133.6 | 4.9% |
XBI Fundamental Data Overview January 31, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 8.82b USD (8.82b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 8.82b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 8.82b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.09% (E(8.82b)/V(8.82b) * Re(9.09%) + (debt-free company))
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)